

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT

PRESENTATIONS OF PHASE II RESEARCH STUDIES OF IMM01 AT THE 2023 ASH ANNUAL MEETING

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that three Phase II research studies of IMM01 have been accepted for presentations at the 2023 American Society of Hematology (the “**ASH**”) Annual Meeting.

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, bringing together the latest and most cutting-edge scientific research in the pathogenesis and clinical treatment of hematologic diseases. The 65th ASH Annual Meeting will take place on December 9, 2023 to December 12, 2023, both online and in-person in San Diego, the United States.

The table below sets forth details of the presentations:

Name of the Research Studies	Publication Number	Publication Type	Presentation Time (Pacific Time)	Website of the Abstract Release
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)	320	Oral presentation	Saturday, December 9, 2023, 4:15 PM	https://ash.confex.com/ash/2023/webprogram/Paper174420.html
IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classical Hodgkin Lymphoma: An Open Label, Multicenter Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity	609	Oral presentation	Sunday, December 10, 2023, 5:00 PM	https://ash.confex.com/ash/2023/webprogram/Paper174829.html
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)	1859	Poster presentation	Saturday, December 9, 2023, 5:30 PM–7:30 PM	https://ash.confex.com/ash/2023/webprogram/Paper181501.html

Please visit the official website of the ASH Annual Meeting:

<https://www.hematology.org/meetings/annual-meeting> for more information.

ABOUT IMM01

IMM01, the Group’s core product, is an innovative molecule targeting cluster of differentiation 47 (CD47). It is the first SIRP α -Fc fusion protein to enter into clinical stage in China. IMM01 designed with immunoglobulin G1 (IgG1) Fc can fully activate macrophages via a dual mechanism — simultaneously blocking the “don’t eat me” signal by disrupting CD47/SIRP α interaction and delivering the “eat me” signal through the engagement of activating Fc-gamma (Fc γ) receptors on macrophages. Furthermore, the CD47-binding domain of IMM01 was specifically engineered to avoid human red blood cell binding. With the differentiated molecule design, IMM01 has achieved a favorable safety profile and demonstrated its ability to activate macrophages.

The Group owns the global intellectual property rights and commercial rights of IMM01. As of the date of this announcement, in relation to IMM01, the Group owned one patent family, which includes issued patents in China, the United States, Japan and the European Union.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM01, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, November 6, 2023

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Song Ziyi as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.